Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis
Authors
- F.N. Albach
- I. Minopoulou
- A. Wilhelm
- R. Biesen
- A. Kleyer
- E. Wiebe
- A. Fleischmann
- M. Frick
- F. Damm
- J. Gogolok
- S. Serve
- B.N. Locher
- D. Borie
- V. Casteleyn
- E. Siegert
- T. Dörner
- T. Alexander
- C. Furth
- J. Zernicke
- K. Movassaghi
- M.L. Hütter-Krönke
- E. Schrezenmeier
- U. Schneider
- L. Bullinger
- G. Krönke
- O. Penack
- D. Simon
Journal
- Rheumatology
Citation
- Rheumatology 64 (6): 4075-4077
Abstract
RHEUMATOLOGY KEY MESSAGE: Anti-CD19 CAR T-cell therapy might represent a therapeutic option for severe SSc and concomitant RA.